Search
amitriptyline/perphenazine (Etrafon, Triavil)
Indications:
-> treatment of moderate to severe anxiety (rarely used)
Contraindications:
1) concurrent use of MAO inhibitors
2) angle-closure glaucoma
3) bone marrow depression Warnings:
1) safety not established for patients < 12 years of age
2) avoid use of alcoholic beverages
pregnancy-category D
safety in lactation -
Dosage: 1 tab PO TID/QID.
Tabs: 2/10, 2/25, 4/10, 4/25, 4/50 mg/mg perphenazine/amitriptyline.
Pharmacokinetics: elimination: liver > kidney.
Adverse effects: see amitriptyline & perphanazine
Drug interactions:
1) increased effect & toxicity:
- cimetidine, methyldopa, propranolol, methylphenidate, increased effect of CNS depressants (including tricyclic antidepressants), adrenergic agents, anticholinergic agents, warfarin, lithium, fluoxetine
2) decreased effect:
- antacids, carbamazepine, barbiturates, anticholinergic agents
3) MAO inhibitors: contraindicated
Interactions
drug adverse effects of antidepressants
General
antidepressant combination
Database Correlations
PUBCHEM cid=165659
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
Components
amitriptyline (Elavil, Endep)
perphenazine (Trilafon)